Gyre : Phase 3 Trial Of Hydronidone In Chronic Hepatitis B Meets Main Goal; Prices $20 Mln Offering

Gyre Therapeutics' Hydronidone (F351) met its primary endpoint in a Phase 3 trial for treating liver fibrosis in chronic hepatitis B patients in China, showing a statistically significant improvement in fibrosis regression versus placebo (52.85% vs. 29.84%, P=0.0002); the company plans to file an NDA in China in Q3 2025 and initiate a Phase 2 trial in the U.S. for MASH-associated fibrosis in H2 2025. Concurrently, Gyre announced a $20 million public offering at $9.00 per share to fund the U.S. trial and other corporate purposes, leading to a 15.25% drop in after-hours trading despite the positive trial results.

Analysis

Gyre Therapeutics (GYRE) reported statistically significant positive results from its pivotal Phase 3 trial of Hydronidone (F351) in China for liver fibrosis in chronic hepatitis B (CHB) patients, with 52.85% of patients receiving Hydronidone achieving a 1-stage regression in liver fibrosis compared to 29.84% for placebo (P=0.0002). These efficacy outcomes, consistent with prior Phase 2 data, were accompanied by a favorable safety profile, with serious adverse events at 4.88% versus 6.45% for placebo and no discontinuations due to adverse events. The company plans an NDA submission in China in Q3 2025 and an IND filing in the U.S. in Q3 2025 to initiate a Phase 2 trial for MASH-associated fibrosis in H2 2025, supported by positive U.S. Phase 1 data. Despite this clinical success, which saw the stock rise 8.10% to $11.21 in regular trading, GYRE shares fell 15.25% in after-hours trading. This sharp decline is attributable to the concurrent announcement of an underwritten public offering of 2.22 million shares priced at $9.00 per share, aiming to raise approximately $20.0 million. The offering price represents a significant discount to the closing price. Proceeds are earmarked for the U.S. Phase 2 MASH trial, R&D, manufacturing, and general corporate purposes, indicating a strategic move to fund further development despite the immediate dilutive impact.

Key Decisions for Investors

• Investors should recognize the significant clinical validation for Hydronidone in CHB liver fibrosis in China, but weigh this against the immediate share price pressure and dilution from the equity offering priced at $9.00.
• Monitor the company's execution on key upcoming milestones, including the Q3 2025 NDA filing in China and the IND submission and subsequent initiation of the Phase 2 MASH trial in the U.S.
• Consider the current valuation post-offering in light of the de-risked CHB asset in China and the potential of the MASH indication in the U.S., balanced by the company's ongoing financing needs for clinical development.